<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Radiation therapy for high-grade gliomas
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Radiation therapy for high-grade gliomas
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Radiation therapy for high-grade gliomas
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Helen A Shih, MD, MS, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Patrick Y Wen, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            April F Eichler, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 18, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         High-grade gliomas are malignant brain tumors that include the most common malignant primary brain tumor in adults, isocitrate dehydrogenase (IDH)-wildtype glioblastoma, as well as grade 3 and 4 IDH-mutant astrocytomas and anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted  (
         <a class="graphic graphic_algorithm graphicRef134946" href="/z/d/graphic/134946.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5211.html" rel="external">
          "Classification and pathologic diagnosis of gliomas, glioneuronal tumors, and neuronal tumors"
         </a>
         .)
        </p>
        <p>
         Most high-grade gliomas are managed with a combined-modality approach, incorporating adjuvant postoperative radiation therapy (RT) and adjuvant chemotherapy following initial surgery. An overview of the use of RT in patients with high-grade glioma is presented here.
        </p>
        <p>
         Other patient management topics that are covered separately include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Initial surgical management of high-grade gliomas (see
         <a class="medical medical_review" href="/z/d/html/5228.html" rel="external">
          "Clinical presentation, diagnosis, and initial surgical management of high-grade gliomas"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Concurrent and adjuvant chemotherapy (see
         <a class="medical medical_review" href="/z/d/html/5207.html" rel="external">
          "Initial treatment and prognosis of IDH-wildtype glioblastoma in adults"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Glioblastoma in older adults (see
         <a class="medical medical_review" href="/z/d/html/15246.html" rel="external">
          "Management of glioblastoma in older adults"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         IDH-mutant astrocytomas and oligodendrogliomas (see
         <a class="medical medical_review" href="/z/d/html/5198.html" rel="external">
          "Treatment and prognosis of IDH-mutant astrocytomas in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5221.html" rel="external">
          "Treatment and prognosis of IDH-mutant, 1p/19q-codeleted oligodendrogliomas in adults"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Recurrent high-grade gliomas (see
         <a class="medical medical_review" href="/z/d/html/5205.html" rel="external">
          "Management of recurrent high-grade gliomas"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          SURGICAL RESECTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         A histologic diagnosis is required for optimal treatment of patients with gliomas. This can be accomplished by surgical resection or with a stereotactic biopsy. Biopsy alone is used in situations where the lesion is not amenable to resection, a meaningful amount of tumor tissue cannot be removed, or the patient's overall clinical condition will not permit a more aggressive surgery.
        </p>
        <p>
         For patients with a newly diagnosed high-grade glioma, maximal surgical resection consistent with preservation of neurologic function is preferred. Although gross total resection is preferred whenever possible, subtotal resection or stereotactic biopsy may be required depending upon the location and extent of the tumor. (See
         <a class="medical medical_review" href="/z/d/html/5228.html" rel="external">
          "Clinical presentation, diagnosis, and initial surgical management of high-grade gliomas", section on 'Extent of resection'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          ADJUVANT RT
         </span>
         <span class="headingEndMark">
          —
         </span>
         High-grade gliomas are infiltrative tumors with microscopic disease extending into the adjacent brain parenchyma to the gross tumor, which is typically defined by the radiographic abnormality. Adjuvant RT directed to residual microscopic and gross disease is not curative but improves local control and survival after resection compared with surgery or chemotherapy alone [
         <a href="#rid2">
          2-9
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Treatment target
         </span>
         <span class="headingEndMark">
          —
         </span>
         Involved field RT is the standard approach for adjuvant RT in patients with high-grade gliomas. The rationale for limiting the RT field is based upon the observation that recurrent high-grade glioma following whole brain RT (WBRT) develops within 2 cm of the original tumor site in 80 to 90 percent of cases, while less than 10 percent are multifocal [
         <a href="#rid10">
          10-13
         </a>
         ].
        </p>
        <p>
         To encompass infiltrating tumor cells, the RT dose (typically 60 Gy) is usually delivered to the tumor plus a margin of radiographically appearing normal tissue. Most commonly, the RT target volume is defined primarily by T2-weighted magnetic resonance imaging (MRI) abnormality best appreciated on a fluid-attenuated inversion recovery (FLAIR) series with a 1.0 to 2.0 cm margin. If the T1 contrast-enhancement volume is used for radiation planning, this is typically a subset of the T2-defined tumor, and a margin of 2.0 to 2.5 cm is often used to define the target volume to be treated to 60 Gy.
        </p>
        <p class="headingAnchor" id="H3209975009">
         <span class="h2">
          Dose selection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adequate doses of RT are required to maximize the survival benefit. In early studies of RT for malignant glioma, patients who had RT doses of 50 to 60 Gy had a longer median survival than those who received lower postoperative RT doses [
         <a href="#rid5">
          5-8
         </a>
         ]. These studies established 60 Gy, delivered over six weeks in 2 Gy fractions, as the standard target dose for glioblastoma [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
         There are no data comparing optimal dose and schedule in anaplastic gliomas versus glioblastoma. However, many radiation oncologists use a dose of 59.4 Gy in 1.8 Gy fractions for grade 3 tumors versus 60 Gy in 2 Gy fractions for grade 4 tumors with the expectation that the 10 percent dose reduction per fraction may lead to reduced late normal tissue effects for patients with projected longer-term survival.
        </p>
        <p>
         Dose escalation above 60 Gy using conventionally fractionated RT, hyperfractionation, brachytherapy, or stereotactic radiosurgical boost has not been shown to provide further benefit [
         <a href="#rid7">
          7,8,15-18
         </a>
         ]. Dose escalation to the contrast-enhancing volume using contemporary techniques continues to be investigated in glioblastoma and is the subject of an ongoing clinical trial (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT02179086%3Fterm%3DNRG-BN001%26cond%3DGlioblastoma%26rank%3D1&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSzh35RvrgLNrXQnXVeh%2FjIk3cFLFckhqDggTmlTSi55ZA5G8zQlNLKJ2Z1c4JO%2F3rblOtewtY8x9abYkik2O72mC4BRDSW0aecvoZVRB6H4rA%3D%3D&amp;TOPIC_ID=5225" target="_blank">
          NCT02179086
         </a>
         ) [
         <a href="#rid19">
          19,20
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H708302804">
         <span class="h2">
          Planning and delivery methods
         </span>
         <span class="headingEndMark">
          —
         </span>
         Three-dimensional conformal RT (3D-CRT) and intensity-modulated RT (IMRT) are two of the most common methods of planning and delivering involved field RT for high-grade gliomas.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h3">
          3D-conformal RT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The use of 3D treatment planning has enabled a significant decrease in the amount of normal brain irradiated as compared with the two-dimensional planning era [
         <a href="#rid21">
          21,22
         </a>
         ].
        </p>
        <p>
         Current 3D-CRT uses computed tomography (CT)-based treatment planning with dosimetric software to create composite treatment plans. Fusion of planning CT with MRI is extremely helpful in assisting with target definition [
         <a href="#rid21">
          21-23
         </a>
         ]. Photons of 6 to 8 megavolts (MV) are most commonly used with three to four or more angled radiation beams.
        </p>
        <p>
         Radiation oncologists work with medical physicists and dosimetrists to design optimal treatment plans. Considerations in treatment planning include beam energy, field size and shape, beam modifiers, irradiated tissue density and heterogeneity, and radiation tolerance of surrounding normal tissues.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h3">
          Intensity-modulated RT
         </span>
         <span class="headingEndMark">
          —
         </span>
         IMRT is a technique that relies upon more advanced radiation planning and delivery software to vary the shapes of radiation beam and dose intensity across each treatment field. IMRT provides particular advantages when the target is juxtaposed with radiation-sensitive structures. IMRT most commonly employs five, seven, or nine treatment beams from different directions, with each field being from a stationary direction, but in which the radiation output varies across the field with time of irradiation. (See
         <a class="medical medical_review" href="/z/d/html/89528.html" rel="external">
          "Radiation therapy techniques in cancer treatment", section on 'Intensity-modulated radiation therapy'
         </a>
         .)
        </p>
        <p>
         Volumetric modulation arc radiotherapy (VMAT) is a form of IMRT that utilizes arc-based treatment delivery in which the radiation source is moving in an arc around the patient while delivering the radiation treatment. VMAT delivery is more efficient and requires approximately half the time that IMRT requires.
        </p>
        <p>
         The application of IMRT and VMAT in the treatment of high-grade gliomas has become increasingly prevalent, as it significantly decreases the volume of normal tissue treated to high doses, which may decrease radiation-related adverse effects [
         <a href="#rid24">
          24
         </a>
         ]. IMRT and VMAT also enable better radiation dose coverage to the parts of the tumor target close to radiation-sensitive structures (eg, optic chiasm and optic nerves), where radiation dose limits result in the tradeoff of lower dose to nearby tumor. IMRT and VMAT can also be used to more safely escalate doses to the tumor, but there are no proven benefits to delivering doses beyond 60 Gy [
         <a href="#rid24">
          24,25
         </a>
         ].
        </p>
        <p>
         The most appropriate application of IMRT in the brain is likely to be when the radiation target approximates radiation-sensitive structures such as the eyes, optic nerves, optic chiasm, or brainstem. The disadvantages of IMRT include increased low-dose radiation distribution to surrounding nontarget tissues and the higher complexity of radiation planning that requires more time.
        </p>
        <p class="headingAnchor" id="H1293406718">
         <span class="h2">
          Side effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute side effects occurring during standard fractionated brain RT are typically mild and manageable with basic supportive care. Fatigue, loss of appetite, radiation dermatitis, and alopecia are the most commonly encountered toxicities during brain RT. Management of these and other side effects is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/7053.html" rel="external">
          "Acute complications of cranial irradiation"
         </a>
         .)
        </p>
        <p>
         There are multiple potential long-term complications of brain irradiation, including neurocognitive toxicity, RT-induced leukoencephalopathy, and endocrinopathies. The use of involved field RT lowers the risk of some but not all of these toxicities compared with WBRT. Risk also varies by dose, age, area of the brain receiving radiation, and concurrent therapies. (See
         <a class="medical medical_review" href="/z/d/html/91670.html" rel="external">
          "Delayed complications of cranial irradiation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3881025088">
         <span class="h2">
          Monitoring during use of concurrent temozolomide
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients receiving
         <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">
          temozolomide
         </a>
         chemotherapy during RT are at risk for hematologic toxicity and hepatotoxicity. Patients require weekly complete blood counts for hematologic monitoring during RT. Liver biochemical tests should be performed at baseline, midway through RT, and before each monthly cycle of temozolomide. (See
         <a class="medical medical_review" href="/z/d/html/5207.html" rel="external">
          "Initial treatment and prognosis of IDH-wildtype glioblastoma in adults", section on 'Side effects and monitoring'
         </a>
         .)
        </p>
        <p>
         Moderate to severe thrombocytopenia is the most common hematologic adverse effect, occurring in approximately 10 to 20 percent of patients [
         <a href="#rid26">
          26
         </a>
         ]. Radiation is not known to increase bleeding risk and can be continued safely during periods of mild to moderate thrombocytopenia. In patients with severe thrombocytopenia (eg, counts fewer than 10,000 to 20,000/microL), some practitioners elect to hold RT until hematologic stability has been achieved.
        </p>
        <p>
         The majority of patients also develop some degree of lymphopenia and are at risk for
         <em>
          Pneumocystis
         </em>
         <em>
          jirovecii
         </em>
         pneumonia (PJP).
         <em>
          Pneumocystis
         </em>
         pneumonia prophylaxis should be administered to all patients receiving daily
         <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">
          temozolomide
         </a>
         during RT. (See
         <a class="medical medical_review" href="/z/d/html/1393.html" rel="external">
          "Treatment and prevention of Pneumocystis pneumonia in patients without HIV", section on 'Prophylaxis'
         </a>
         .)
        </p>
        <p>
         The role of adjuvant chemotherapy in patients with high-grade glioma is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5207.html" rel="external">
          "Initial treatment and prognosis of IDH-wildtype glioblastoma in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5221.html" rel="external">
          "Treatment and prognosis of IDH-mutant, 1p/19q-codeleted oligodendrogliomas in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1011337447">
         <span class="h2">
          Older adults
         </span>
         <span class="headingEndMark">
          —
         </span>
         De-escalated therapy is often appropriate for older adults with high-grade gliomas and those with poor performance status. The role of RT in older adults and potential modifications in dose and schedule are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/15246.html" rel="external">
          "Management of glioblastoma in older adults", section on 'Radiation therapy alone'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3026966222">
         <span class="h1">
          ASSESSMENT OF RESPONSE AND PROGRESSION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patient management decisions require an assessment of both initial response to treatment as well as surveillance and subsequent considerations at the time of progressive disease.
        </p>
        <p class="headingAnchor" id="H3577067188">
         <span class="h2">
          Clinical and neuroimaging follow-up
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients undergoing RT for high-grade glioma require regular clinical follow up to manage symptoms and glucocorticoid dosing and to monitor for adverse effects of treatment. MRI is performed approximately one month after completion of RT to assess initial response. (See
         <a class="medical medical_review" href="/z/d/html/5207.html" rel="external">
          "Initial treatment and prognosis of IDH-wildtype glioblastoma in adults", section on 'Follow-up and monitoring'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2835947805">
         <span class="h2">
          Pseudoprogression
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pseudoprogression is a subacute treatment-related effect with MRI features mimicking tumor progression that most commonly occurs within the first three months after completion of chemoradiation for high-grade glioma. The diagnosis is typically made retrospectively, based upon spontaneous improvement or stabilization of imaging findings in the setting of continuation of the original therapy for at least six months.
        </p>
        <p>
         Pseudoprogression is difficult to differentiate from true progression but should be considered in patients who develop new or enlarging enhancement within the high-dose RT field within the first three to six months after completion of RT with concurrent
         <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">
          temozolomide
         </a>
         , especially those with methylguanine-DNA-methyltransferase (MGMT) promoter hypermethylated glioblastoma. (See
         <a class="medical medical_review" href="/z/d/html/5205.html" rel="external">
          "Management of recurrent high-grade gliomas", section on 'Early progression versus pseudoprogression'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          REIRRADIATION
         </span>
        </p>
        <p class="headingAnchor" id="H901173587">
         <span class="h2">
          Patients with radiation-induced gliomas
         </span>
         <span class="headingEndMark">
          —
         </span>
         Previous exposure to radiation of any dose is a known risk factor for the subsequent development of both benign and malignant brain tumors, including gliomas. Treatment of gliomas in patients with a history of prior cranial irradiation is a particular concern because of the increased risk of late radiation-related side effects, including neurocognitive deficits and radiation necrosis. (See
         <a class="medical medical_review" href="/z/d/html/5214.html" rel="external">
          "Risk factors for brain tumors", section on 'Ionizing radiation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/91670.html" rel="external">
          "Delayed complications of cranial irradiation"
         </a>
         .)
        </p>
        <p>
         In general, partial brain reirradiation to therapeutic doses for gliomas is considered acceptable with at least a five-year interval between radiation exposures. The survival benefit and safety of reirradiation as a component of therapy in glioma patients with prior cranial irradiation was supported by a review of the literature that identified a total of 92 cases of secondary high-grade glioma related to prior brain RT (mostly for a prior brain tumor or leukemia), of which 35 underwent reirradiation to a median dose of 50 Gy [
         <a href="#rid27">
          27
         </a>
         ]. The one- and two-year survival rates were increased compared with the 57 patients who were not reirradiated (59 versus 15, and 21 versus 3 percent, respectively).
        </p>
        <p class="headingAnchor" id="H2056580196">
         <span class="h2">
          Role in recurrent glioblastoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         The role of reirradiation in patients with recurrent glioblastoma is uncertain, and clinical trials are ongoing. While reirradiation has been shown to be feasible in selected patients in retrospective studies, there is no consensus regarding treatment volume, dose, and fractionation, or factors that predict benefit (eg, tumor volume, interval since prior radiation, performance status, molecular tumor characteristics, prior treatments) [
         <a href="#rid28">
          28
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5205.html" rel="external">
          "Management of recurrent high-grade gliomas", section on 'Reirradiation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          OTHER TECHNIQUES
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of other RT techniques have been evaluated in patients with high-grade glioma, but do not have an established role.
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Interstitial brachytherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Interstitial brachytherapy uses the intraoperative placement of radioisotope seeds (most commonly iodine-125 or cesium-131) into the tumor or resection cavity. These seeds release low-dose rate (LDR) irradiation for the duration of the life of the radioisotope [
         <a href="#rid29">
          29,30
         </a>
         ]. Brachytherapy permits the delivery of a large radiation dose to the tumor volume, with rapid falloff in surrounding tissues.
        </p>
        <p>
         Despite the theoretical dosimetric and radiobiologic advantages of brachytherapy, randomized clinical trials have shown marginal or no benefit for the use of brachytherapy in the treatment of high-grade gliomas [
         <a href="#rid16">
          16,17,30,31
         </a>
         ].
        </p>
        <p>
         Brachytherapy is technically complex, and its applicability is limited because the effective radiation dose is limited to within a few millimeters of the seeds, and gliomas are inherently infiltrative into normal-appearing brain. Given these characteristics, the full extent of disease is not effectively treated by brachytherapy.
        </p>
        <p>
         These constraints eliminate up to 75 percent of high-grade glioma patients from consideration for brachytherapy [
         <a href="#rid32">
          32
         </a>
         ]. Interest in brachytherapy has waned with the use of intensity-modulated RT (IMRT) and stereotactic RT techniques to deliver a radiation boost, both of which offer dosimetric advantages similar to that of brachytherapy.
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Particle RT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Charged heavy particles (helium and neon ions), protons (light-charged particles), and neutrons have been used alone and as a boost to conventional photon radiation. The physical properties of charge particle beams that are useful clinically are their finite path lengths and the ability to concentrate the majority of their dose at the end of their path length, with little exit dose [
         <a href="#rid33">
          33
         </a>
         ]. The latter property permits a reduction of radiation exposure to surrounding normal tissue. (See
         <a class="medical medical_review" href="/z/d/html/89528.html" rel="external">
          "Radiation therapy techniques in cancer treatment", section on 'Particle therapy'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Proton beam RT – Proton beam RT is becoming more widely available and is commonly used to treat pediatric brain tumors such as medulloblastoma. There are limited data on its potential utility in high-grade gliomas, much less superiority, as compared with conformal photon RT. Whereas the highly conformal radiation delivery with the use of protons can permit dose escalation, its potential application in treating glioblastoma may be better suited to simply limiting RT-related side effects. The role of dose-escalated protons is being tested in an ongoing multicenter trial (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02179086%3Fterm%3DNRG%2BBN001%26rank%3D1&amp;token=nbsXe3i4qfUea5RCPRHtOS7yhoEzH%2BMCpwZ1%2F1ekxPOC0Eop1EyZ7VetjkkaJ3UeXBVBIsRxfGAdhUuX1k%2BxRTENqoLs3BlVqp1Jvhv%2BhLw%3D&amp;TOPIC_ID=5225" target="_blank">
          NCT02179086
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/91670.html" rel="external">
          "Delayed complications of cranial irradiation", section on 'Brain tissue necrosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Neutrons – Boron neutron capture therapy (BNCT) has evolved to enable irradiation of deeper tissues using nonoperative techniques. Several institutions have reported experiences with BNCT in patients with glioblastoma without clear benefit to photon techniques [
         <a href="#rid34">
          34-36
         </a>
         ]. Lacking a clear benefit, the added complexity of BNCT makes it less attractive to use than standard RT.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Radiation sensitizers
         </span>
         <span class="headingEndMark">
          —
         </span>
         Radiation sensitizers are compounds that are given concurrently with RT in an effort to increase its therapeutic effect. Several classes of radiosensitizers have been studied in clinical trials, but none of these have been approved for high-grade gliomas or are in widespread use.
        </p>
        <p class="headingAnchor" id="H2560434803">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/130511.html" rel="external">
          "Society guideline links: Primary brain tumors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H33271751">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/82941.html" rel="external">
          "Patient education: Glioblastoma (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topic (see
         <a class="medical medical_patient" href="/z/d/html/855.html" rel="external">
          "Patient education: High-grade glioma in adults (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Introduction
         </strong>
         – Involved field radiation therapy (RT) is a standard component of initial multimodality therapy in patients with isocitrate dehydrogenase (IDH)-wildtype glioblastoma as well as high-grade IDH-mutant diffuse gliomas  (
         <a class="graphic graphic_algorithm graphicRef134946" href="/z/d/graphic/134946.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Adjuvant RT'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/5207.html" rel="external">
          "Initial treatment and prognosis of IDH-wildtype glioblastoma in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dose selection
         </strong>
         – Adequate doses of RT are required to maximize the survival benefit. Typical doses of RT used for high-grade glioma are 59.4 Gy in 1.8 Gy fractions for grade 3 tumors and 60 Gy in 2 Gy fractions for glioblastoma. Dose escalation above 60 Gy has not been shown to provide further benefit. (See
         <a class="local">
          'Dose selection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment target
         </strong>
         –
         <strong>
         </strong>
         RT is delivered to the tumor plus a margin of radiographically apparently normal tissue to encompass infiltrating tumor cells. Intensity-modulated RT (IMRT), including the subtype of volumetric modulation arc radiotherapy (VMAT), is increasingly the preferred standard RT technique to achieve best radiation dose coverage to the clinical target(s) with minimization of collateral high doses to surrounding normal tissues. (See
         <a class="local">
          'Treatment target'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Side effects
         </strong>
         – Fatigue, loss of appetite, radiation dermatitis, and alopecia are the most commonly encountered side effects during brain RT. Patients receiving
         <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">
          temozolomide
         </a>
         chemotherapy during RT are at risk for hematologic toxicity and should be monitored with weekly complete blood counts. (See
         <a class="local">
          'Side effects'
         </a>
         above and
         <a class="local">
          'Monitoring during use of concurrent temozolomide'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Response assessment
         </strong>
         – Brain MRI with contrast should be obtained approximately four weeks after completion of RT, then every two to four months for two to three years, and less frequently thereafter. (See
         <a class="local">
          'Assessment of response and progression'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Reirradiation
         </strong>
         – In patients with radiation-induced gliomas related to prior history of brain RT, therapeutic reirradiation can generally be performed with at least a five-year interval between radiation exposures. The role of reirradiation in patients with recurrent high-grade gliomas is uncertain, and clinical trials are ongoing. (See
         <a class="local">
          'Patients with radiation-induced gliomas'
         </a>
         above and
         <a class="local">
          'Role in recurrent glioblastoma'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3390672860">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Tracy Batchelor, MD, MPH, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Central Nervous System Tumours, 5th ed, WHO Classification of Tumours Editorial Board (Ed), International Agency for Research on Cancer, 2021.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980; 303:1323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andersen AP. Postoperative irradiation of glioblastomas. Results in a randomized series. Acta Radiol Oncol Radiat Phys Biol 1978; 17:475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walker MD, Alexander E Jr, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 1978; 49:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coffey RJ, Lunsford LD, Taylor FH. Survival after stereotactic biopsy of malignant gliomas. Neurosurgery 1988; 22:465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 1979; 5:1725.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang CH, Horton J, Schoenfeld D, et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer 1983; 52:997.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gliomas--re-evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group. NCI Monogr 1988; :279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corso CD, Bindra RS, Mehta MP. The role of radiation in treating glioblastoma: here to stay. J Neurooncol 2017; 134:479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology 1980; 30:907.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wallner KE, Galicich JH, Krol G, et al. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 1989; 16:1405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choucair AK, Levin VA, Gutin PH, et al. Development of multiple lesions during radiation therapy and chemotherapy in patients with gliomas. J Neurosurg 1986; 65:654.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liang BC, Thornton AF Jr, Sandler HM, Greenberg HS. Malignant astrocytomas: focal tumor recurrence after focal external beam radiation therapy. J Neurosurg 1991; 75:559.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cabrera AR, Kirkpatrick JP, Fiveash JB, et al. Radiation therapy for glioblastoma: Executive summary of an American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. Pract Radiat Oncol 2016; 6:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys 2004; 60:853.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Selker RG, Shapiro WR, Burger P, et al. The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery 2002; 51:343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laperriere NJ, Leung PM, McKenzie S, et al. Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int J Radiat Oncol Biol Phys 1998; 41:1005.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh R, Lehrer EJ, Wang M, et al. Dose Escalated Radiation Therapy for Glioblastoma Multiforme: An International Systematic Review and Meta-Analysis of 22 Prospective Trials. Int J Radiat Oncol Biol Phys 2021; 111:371.
          </a>
         </li>
         <li class="breakAll">
          NCT02179086. https://www.clinicaltrials.gov/ct2/show/NCT02179086?term=NRG-BN001&amp;cond=Glioblastoma&amp;rank=1.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsien CI, Brown D, Normolle D, et al. Concurrent temozolomide and dose-escalated intensity-modulated radiation therapy in newly diagnosed glioblastoma. Clin Cancer Res 2012; 18:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ten Haken RK, Thornton AF Jr, Sandler HM, et al. A quantitative assessment of the addition of MRI to CT-based, 3-D treatment planning of brain tumors. Radiother Oncol 1992; 25:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thornton AF Jr, Hegarty TJ, Ten Haken RK, et al. Three-dimensional treatment planning of astrocytomas: a dosimetric study of cerebral irradiation. Int J Radiat Oncol Biol Phys 1991; 20:1309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glatstein E, Lichter AS, Fraass BA, et al. The imaging revolution and radiation oncology: use of CT, ultrasound, and NMR for localization, treatment planning and treatment delivery. Int J Radiat Oncol Biol Phys 1985; 11:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Narayana A, Yamada J, Berry S, et al. Intensity-modulated radiotherapy in high-grade gliomas: clinical and dosimetric results. Int J Radiat Oncol Biol Phys 2006; 64:892.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J Clin Oncol 2002; 20:1635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gerber DE, Grossman SA, Zeltzman M, et al. The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas. Neuro Oncol 2007; 9:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paulino AC, Mai WY, Chintagumpala M, et al. Radiation-induced malignant gliomas: is there a role for reirradiation? Int J Radiat Oncol Biol Phys 2008; 71:1381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Howard SP, Krauze A, Chan MD, et al. The evolving role for re-irradiation in the management of recurrent grade 4 glioma. J Neurooncol 2017; 134:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marin LA, Smith CE, Langston MY, et al. Response of glioblastoma cell lines to low dose rate irradiation. Int J Radiat Oncol Biol Phys 1991; 21:397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sneed PK, Lamborn KR, Larson DA, et al. Demonstration of brachytherapy boost dose-response relationships in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1996; 35:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koot RW, Maarouf M, Hulshof MC, et al. Brachytherapy: Results of two different therapy strategies for patients with primary glioblastoma multiforme. Cancer 2000; 88:2796.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilson CB, Larson DA, Gutin PH. Radiosurgery: a new application? J Clin Oncol 1992; 10:1373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kirkpatrick JP, Laack NN, Shih HA, Gondi V. Management of GBM: a problem of local recurrence. J Neurooncol 2017; 134:487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kageji T, Mizobuchi Y, Nagahiro S, et al. Correlation between radiation dose and histopathological findings in patients with gliblastoma treated with boron neutron capture therapy (BNCT). Appl Radiat Isot 2014; 88:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henriksson R, Capala J, Michanek A, et al. Boron neutron capture therapy (BNCT) for glioblastoma multiforme: a phase II study evaluating a prolonged high-dose of boronophenylalanine (BPA). Radiother Oncol 2008; 88:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kawabata S, Miyatake S, Kuroiwa T, et al. Boron neutron capture therapy for newly diagnosed glioblastoma. J Radiat Res 2009; 50:51.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5225 Version 34.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Central Nervous System Tumours, 5th ed, WHO Classification of Tumours Editorial Board (Ed), International Agency for Research on Cancer, 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7001230" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/216238" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Postoperative irradiation of glioblastomas. Results in a randomized series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/355604" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2452376" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Survival after stereotactic biopsy of malignant gliomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/231022" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : An analysis of dose-effect relationship in the radiotherapy of malignant gliomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6349785" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3281031" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Combined modality approach to treatment of malignant gliomas--re-evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28271281" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : The role of radiation in treating glioblastoma: here to stay.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6252514" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Assumptions in the radiotherapy of glioblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2542195" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3021931" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Development of multiple lesions during radiation therapy and chemotherapy in patients with gliomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1653309" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Malignant astrocytomas: focal tumor recurrence after focal external beam radiation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27211230" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Radiation therapy for glioblastoma: Executive summary of an American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15465203" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12182772" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9719109" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33991621" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Dose Escalated Radiation Therapy for Glioblastoma Multiforme: An International Systematic Review and Meta-Analysis of 22 Prospective Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33991621" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Dose Escalated Radiation Therapy for Glioblastoma Multiforme: An International Systematic Review and Meta-Analysis of 22 Prospective Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22065084" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Concurrent temozolomide and dose-escalated intensity-modulated radiation therapy in newly diagnosed glioblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1332134" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : A quantitative assessment of the addition of MRI to CT-based, 3-D treatment planning of brain tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2045305" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Three-dimensional treatment planning of astrocytomas: a dosimetric study of cerebral irradiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3882642" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : The imaging revolution and radiation oncology: use of CT, ultrasound, and NMR for localization, treatment planning and treatment delivery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16458777" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Intensity-modulated radiotherapy in high-grade gliomas: clinical and dosimetric results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11896114" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17108062" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18262733" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Radiation-induced malignant gliomas: is there a role for reirradiation?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28386661" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : The evolving role for re-irradiation in the management of recurrent grade 4 glioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2061116" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Response of glioblastoma cell lines to low dose rate irradiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8641924" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Demonstration of brachytherapy boost dose-response relationships in glioblastoma multiforme.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10870063" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Brachytherapy: Results of two different therapy strategies for patients with primary glioblastoma multiforme.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1517780" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Radiosurgery: a new application?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28378194" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Management of GBM: a problem of local recurrence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24480727" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Correlation between radiation dose and histopathological findings in patients with gliblastoma treated with boron neutron capture therapy (BNCT).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18336940" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Boron neutron capture therapy (BNCT) for glioblastoma multiforme: a phase II study evaluating a prolonged high-dose of boronophenylalanine (BPA).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18957828" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Boron neutron capture therapy for newly diagnosed glioblastoma.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
